Publications

Add filters (0)

12 results

The inflammatory endotype in osteoarthritis: Reflections from the 2024 OARSI clinical trials symposium (CTS) with a special emphasis on feasibility for clinical development.

June 1, 2025

Osteoarthr Cartil Open

Abstract OBJECTIVE The inflammatory endotype is arguably one of the most well-established endotype in osteoarthritis (OA). While endotyping holds promise for advancing drug development, numerous potential challenges must be considered, addressed and resolved before successful clinical outcomes can be achieved. DESIGN Since 2017, the Osteoarthritis Research Society International (OARSI) has hosted the Clinical Trials Symposium […]

Read publication

Association between type III collagen degradation and local tissue damage of a single joint.

December 1, 2024

Osteoarthr Cartil Open

Abstract OBJECTIVE The development of disease-modifying drugs is limited by OA’s heterogeneity and the challenge of defining clinical endpoints. Serological biomarkers are considered potential surrogate endpoints, but their contribution from single joints to systemic levels in OA patients is unclear. In this exploratory study we longitudinally assessed systemic biomarker levels’ response to tissue damage and […]

Read publication

Development and validation of a machine learning-supported strategy of patient selection for osteoarthritis clinical trials: the IMI-APPROACH study.

December 1, 2023

Osteoarthr Cartil Open

Abstract OBJECTIVES To efficiently assess the disease-modifying potential of new osteoarthritis treatments, clinical trials need progression-enriched patient populations. To assess whether the application of machine learning results in patient selection enrichment, we developed a machine learning recruitment strategy targeting progressive patients and validated it in the IMI-APPROACH knee osteoarthritis prospective study. DESIGN We designed a […]

Read publication

Joint biomarker response to mechanical stimuli in osteoarthritis – A scoping review.

December 1, 2023

Osteoarthr Cartil Open

Abstract OBJECTIVE Arthritic cartilage is primed for mechanical damage. Joint biochemical markers (JBM) could provide insight into the impact of mechanical stimulation on joint tissue turnover in osteoarthritis (OA) of potential use in clinical OA research and practice. However, existing studies of the acute impact of physical activities (PA) on JBM often contain risks of […]

Read publication

Pathological tissue formation and degradation biomarkers correlate with patient reported pain outcomes: an explorative study.

September 1, 2023

Osteoarthr Cartil Open

Abstract BACKGROUND The lack of disease modifying drugs in Osteoarthritis (OA) may be attributed to the difficulty in robust response based on patient-reported outcomes (PROs) linked to drug mechanism of action. Joint tissue turnover biomarkers are associated with disease progression. A subset of patients has elevated serum levels of CRP metabolite (CRPM). This explorative study […]

Read publication

Dynamic compression inhibits cytokine-mediated type II collagen degradation.

December 1, 2022

Osteoarthr Cartil Open

Abstract OBJECTIVE To examine the effect of dynamic compressive loading applied intermittently on bovine cartilage explants stimulated with proinflammatory cytokines over 21 days. DESIGN Cartilage explants were cultured for 21 days with Oncostatin M and TNFα (O ​+ ​T) [10/5 ​ng/mL] or in culture medium alone (w/o). The explants were either left free-swelling or subjected to dynamic compressive […]

Read publication

Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development – Should future studies focus on disease activity, rather than status?

September 1, 2022

Osteoarthr Cartil Open

Abstract OBJECTIVE Osteoarthritis (OA) is heterogeneous disease, for which drug development has proven to be challenging, both facilitated and hampered by changing guidelines. This is evident by the current lack of approved treatments, which improve joint function and delay joint failure. There is a need to bring together key stakeholders to discuss, align and enhance […]

Read publication

A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis.

December 1, 2021

Osteoarthr Cartil Open

Abstract OBJECTIVES There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and discusses its potential as a noninvasive translational biomarker. METHODS A type II collagen specific neoepitope […]

Read publication

Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum.

June 1, 2021

Osteoarthr Cartil Open

Abstract OBJECTIVE Cartilage degradation is a hallmark of osteoarthritis (OA). Aggrecan, a major proteoglycan of articular cartilage extracellular matrix (ECM), is degraded by ADAMTS-5 resulting in the release of ARGS-G2 fragments to synovial fluid and circulation. The aim was to quantify ARGS-G2 in the serum of OA patients using the huARGS immunoassay. METHODS The immunoassay […]

Read publication

Colony housing promotes structural and functional changes during surgically induced osteoarthritis in rats.

December 1, 2020

Osteoarthr Cartil Open

Abstract OBJECTIVE The aim of the study was to investigate how social housing with high locomotion activity affects experimental osteoarthritis (OA) in rats. DESIGN Rats were housed either conventionally in type IV cages in pairs or in rat colony cages (RCC) on 4 levels interconnected by jump holes or staircase in groups of 48. OA […]

Read publication